Cargando…

Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis

Polypharmacy (PP) occurs in patients with type 2 diabetes (T2DM) owing to multimorbidity. We evaluated concomitant PP and medication adherence in T2DM 3 years after initiation of administration of a hypoglycaemic agent using a nationwide claim-based database in Japan. Factors associated with medicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Horii, Takeshi, Iwasawa, Makiko, Kabeya, Yusuke, Atuda, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736933/
https://www.ncbi.nlm.nih.gov/pubmed/31506542
http://dx.doi.org/10.1038/s41598-019-49424-2
_version_ 1783450576256761856
author Horii, Takeshi
Iwasawa, Makiko
Kabeya, Yusuke
Atuda, Koichiro
author_facet Horii, Takeshi
Iwasawa, Makiko
Kabeya, Yusuke
Atuda, Koichiro
author_sort Horii, Takeshi
collection PubMed
description Polypharmacy (PP) occurs in patients with type 2 diabetes (T2DM) owing to multimorbidity. We evaluated concomitant PP and medication adherence in T2DM 3 years after initiation of administration of a hypoglycaemic agent using a nationwide claim-based database in Japan. Factors associated with medication PP and imperfect adherence were identified using multivariable logistic regression. PP was defined as using ≥6 medications. Patients with proportion of days covered (PDC) of <80% were defined as having poor medication adherence. A total of 884 patients were analysed. Multivariate analysis revealed that age, total number of consultations and body mass index (BMI) are factors that influence PP. Factors associated with PDC < 80% were 2–3, 4–5 and ≥ 6 medications compared with 1 medication, male sex, <17 consultations and age 50–59 and ≥ 60 years compared with <40 years. In conclusion, older age, high total number of consultations and BMI ≥ 25 kg/m(2) are risk factors for PP. PP influenced good medication adherence at the end of the observation period.
format Online
Article
Text
id pubmed-6736933
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67369332019-09-20 Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis Horii, Takeshi Iwasawa, Makiko Kabeya, Yusuke Atuda, Koichiro Sci Rep Article Polypharmacy (PP) occurs in patients with type 2 diabetes (T2DM) owing to multimorbidity. We evaluated concomitant PP and medication adherence in T2DM 3 years after initiation of administration of a hypoglycaemic agent using a nationwide claim-based database in Japan. Factors associated with medication PP and imperfect adherence were identified using multivariable logistic regression. PP was defined as using ≥6 medications. Patients with proportion of days covered (PDC) of <80% were defined as having poor medication adherence. A total of 884 patients were analysed. Multivariate analysis revealed that age, total number of consultations and body mass index (BMI) are factors that influence PP. Factors associated with PDC < 80% were 2–3, 4–5 and ≥ 6 medications compared with 1 medication, male sex, <17 consultations and age 50–59 and ≥ 60 years compared with <40 years. In conclusion, older age, high total number of consultations and BMI ≥ 25 kg/m(2) are risk factors for PP. PP influenced good medication adherence at the end of the observation period. Nature Publishing Group UK 2019-09-10 /pmc/articles/PMC6736933/ /pubmed/31506542 http://dx.doi.org/10.1038/s41598-019-49424-2 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Horii, Takeshi
Iwasawa, Makiko
Kabeya, Yusuke
Atuda, Koichiro
Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis
title Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis
title_full Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis
title_fullStr Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis
title_full_unstemmed Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis
title_short Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis
title_sort polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: a japanese database analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736933/
https://www.ncbi.nlm.nih.gov/pubmed/31506542
http://dx.doi.org/10.1038/s41598-019-49424-2
work_keys_str_mv AT horiitakeshi polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis
AT iwasawamakiko polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis
AT kabeyayusuke polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis
AT atudakoichiro polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis